These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21791662)

  • 1. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
    Forestier N; Larrey D; Marcellin P; Guyader D; Patat A; Rouzier R; Smith PF; Qin X; Lim S; Bradford W; Porter S; Seiwert SD; Zeuzem S
    J Infect Dis; 2011 Aug; 204(4):601-8. PubMed ID: 21791662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
    Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
    J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
    Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
    J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
    Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
    Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
    Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
    Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
    Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R
    Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
    Deutsch M; Papatheodoridis GV
    Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
    Gane EJ; Rouzier R; Hassanein T; Stedman CA; Mazur W; Kupcova V; Le Pogam S; Eng S; Voulgari A; Morcos PN; Brennan BJ; Scalori A; Thommes J
    Hepatol Int; 2016 May; 10(3):478-87. PubMed ID: 26886127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
    Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
    Everson G; Cooper C; Hézode C; Shiffman ML; Yoshida E; Beltran-Jaramillo T; Andreone P; Bruno S; Ferenci P; Zeuzem S; Brunda M; Le Pogam S; Nájera I; Zhou J; Navarro MT; Voulgari A; Shulman NS; Yetzer ES
    Liver Int; 2015 Jan; 35(1):108-19. PubMed ID: 24517252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
    Feld JJ; Jacobson IM; Jensen DM; Foster GR; Pol S; Tam E; Jablkowski M; Berak H; Vierling JM; Yoshida EM; Perez-Gomez HR; Scalori A; Hooper GJ; Tavel JA; Navarro MT; Shahdad S; Kulkarni R; Le Pogam S; Nájera I; Eng S; Lim CY; Shulman NS; Yetzer ES
    J Hepatol; 2015 Feb; 62(2):294-302. PubMed ID: 25239078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
    Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
    Gane EJ; Pockros PJ; Zeuzem S; Marcellin P; Shikhman A; Bernaards C; Zhou J; Yetzer ES; Ballester R; Dwyer C; Tong X; Nájera I; Bertasso A; Hammond J; Kindrick A; Morcos PN; Smith P; Stancic S; Shulman NS
    Liver Int; 2015 Jan; 35(1):79-89. PubMed ID: 24814388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.